Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Oncolytics Biotech, Inc. Common Shares

ONCY

Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.

Last trade $0.3661
Day change +$0.0262 (+7.71%)
Day range $0.332 – $0.371
Volume 1,244,835
Market cap $46M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$46.29M
Price / earnings
—
Price / book
2.26×
Price / sales
—
EV / sales
—
EV / EBITDA
-1.83×

Profitability

Earnings per share
-$0.10
Return on assets
-61.63%
Return on equity
-69.32%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
8.85×
Quick ratio
8.85×
Cash ratio
7.92×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$15.41M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ONCY, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q1 FY2016 Mar 31, 2016Q4 FY2015 Dec 31, 2015Q3 FY2015 Sep 30, 2015Q2 FY2015 Jun 30, 2015
Revenue$0$0$0$0————
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0————
Selling, general and administrative$5.12M$4.73M$2.74M$2.22M————
Research and development$4.26M$4.55M$1.92M$2.8M$2.73M$2M$1.7M$2.47M
Total operating expenses$9.38M$9.28M$4.65M$5.02M$4.09M$3.54M$2.88M$3.89M
Operating income-$9.38M-$9.28M-$4.65M-$5.02M-$4.09M-$3.54M-$2.88M-$3.89M
Interest expense$0$0$0$0————
Income before taxes-$9.34M-$9.24M-$5.22M-$4.71M-$4.02M-$3.49M-$2.83M-$3.85M
Income taxes$101K$0$61K$0-$145$6.46K-$4.07K$771
Net income-$9.44M-$9.24M-$5.28M-$4.71M-$4.02M-$3.5M-$2.82M-$3.85M
Net income attributable to common shareholders-$9.44M-$9.24M-$5.28M-$4.71M-$4.02M-$3.5M-$2.82M-$3.85M
EBITDA-$9.36M-$9.27M-$4.63M-$5M-$4.04M-$3.54M-$2.84M-$3.85M
Basic earnings per share-$0.08-$0.08-$0.06-$0.06-$0.29-$0.29-$0.19-$0.29
Diluted earnings per share-$0.08-$0.08-$0.06-$0.06-$0.29-$0.29-$0.19-$0.29

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Colorectal Cancer Market Set for Significant Growth During the Forecast Period (2026–2036), Due to the Emergence of Emerging Targets such as KRAS G12C, NTRK Fusions, and PIK3CA Mutations | DelveInsight

The colorectal cancer market is projected to grow significantly from 2026-2036, driven by rising incidence rates, increased disease awareness, and adoption of targeted therapies and immunotherapies. The market was valued at approximately USD 13 billion in 2025. Key growth drivers include emerging therapies targeting KRAS G12C, NTRK fusions, and PIK3CA mutations, with major pharmaceutical companies launching innovative treatments. The US accounts for the largest market share among the 7 major markets analyzed.

GlobeNewswire Inc.

Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors

Oncolytics Biotech announced translational data from GOBLET and AWARE-1 trials demonstrating that pelareorep induces both innate and adaptive immune responses capable of controlling tumor growth. Data shows expansion of tumor-specific T cells and mutant KRAS-specific clones correlating with tumor regression in pancreatic cancer, and increased immune gene expression in breast cancer. The company also reported durable responses in colorectal cancer and alignment with FDA on a planned pivotal anal cancer study.

GlobeNewswire Inc.

"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies

A new generation of immuno-oncology therapies targeting historically immunotherapy-resistant solid tumors like prostate and pancreatic cancer is advancing rapidly through clinical trials in 2026. Four distinct mechanistic approaches—including NK cell engagers, oncolytic virus immune-primers, and tumor microenvironment-conditional antibodies—are being developed by multiple biotech companies, with over $1.7 billion in dealmaking activity. GT Biopharma's GTB-5550 NK cell engager and Vir Biotechnology's VIR-5500 PSMA-targeted T-cell engager represent leading programs in this emerging therapeutic landscape.

GlobeNewswire Inc.

The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology

Institutional investors are rotating capital toward clinical-stage biotech companies focused on precision medicine, with the oncology precision medicine market projected to reach $303 billion by 2035. Five companies—Oncolytics Biotech, OS Therapies, Sensei Biotherapeutics, Atossa Therapeutics, and Tango Therapeutics—are advancing promising cancer treatments with strong clinical data and FDA support, positioning themselves for potential M&A activity as major pharma companies seek differentiated assets.

Benzinga

New Treatment Modalities Are Reaching Cancers That Resisted Everything Else

Several biotech companies are advancing novel cancer treatments through clinical development. Oncolytics Biotech received FDA Fast Track Designation for pelareorep in KRAS-mutant colorectal cancer, showing doubled survival benefits. Novocure gained FDA approval for Optune Pax for pancreatic cancer. Perspective Therapeutics presented positive interim data for its radiopharmaceutical VMT-α-NET. ImmunityBio launched a Phase 2 trial for its CAR-NK cell therapy combined with IL-15 superagonist. Nuvation Bio expanded its Phase 3 trial for safusidenib in IDH1-mutant glioma.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.